SynthesisPloS one2014

Cardiometabolic risks of blonanserin and perospirone in the management of schizophrenia: a systematic review and meta-analysis of randomized controlled trials.

Taro Kishi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.